Ferric Maltol

Ferric Maltol is a pharmaceutical compound that is used to treat iron deficiency anemia. It is an iron-containing compound that is a complex of ferric iron and maltol, a derivative of pyrone. Ferric maltol is also known as iron(III) maltol, feraccru, and Keryx Biopharmaceuticals.

The molecular structure of ferric maltol is a complex of one ferric ion (Fe3+) and three maltol molecules (C6H6O3). The chemical formula for ferric maltol is C24H20FeO12. The complex has a characteristic red-brown color and is soluble in water.

Manufacturers of Ferric Maltol in India

Ferric Maltol is an orally administered medication that is used to treat iron deficiency anemia in patients with chronic kidney disease who are receiving dialysis. It works by increasing the amount of iron in the body, which is necessary for the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. For the past 60 years, WBCIL has undoubtedly been one of the top manufacturers of Ferric Maltol in India.

Some of the characteristics of ferric maltol include its high bioavailability, which means that a significant amount of the drug is absorbed by the body. It is also well-tolerated by patients, with minimal side effects. In rare cases, it may cause serious allergic reactions or liver problems. It is important to discuss any potential side effects and risks with your healthcare provider before taking this medication.

Molecular Formula – C18H15FeO9
Molecular Weight – 431.2 gm/mol
Melting Point – 300° C
CAS No. – 33725-54-1
Shelf Life – 36 months
Storage Advice – should be kept in a dry and dark place at 0° C – 4° C for the short term (days to weeks) or -20° C for the long term (months to years).
Packing Size –
HSN Code –

Features – White solid powder.
Solubility – 4.5-12mg/mL
pH Range – 11.6
AUC – 0.022-0.205h µg/mL
Iron – 30 gm

Treatment of iron deficiency anemia in patients with IBD: Ferric maltol is used to treat iron deficiency anemia in adult patients with IBD who have not responded to other oral iron therapies.

Reduced gastrointestinal side effects: Ferric Maltol has been found to have fewer gastrointestinal side effects than other oral iron therapies, such as ferrous sulfate, which can cause constipation, diarrhea, and other gastrointestinal problems.

Improved compliance: Because ferric Maltol has fewer side effects and is absorbed directly into the bloodstream, it may improve patient compliance with iron therapy.

Greater efficacy: Ferric Maltol has been found to be more effective in increasing hemoglobin levels and replenishing iron stores in patients with IBD than other oral iron therapies.

Improved quality of life: It is to improve the quality of life in patients with IBD who suffer from iron deficiency anemia, which can cause fatigue, weakness, and other symptoms.

Fewer gastrointestinal side effects: It has fewer gastrointestinal side effects than other oral iron therapies, which can cause constipation, diarrhea, and other gastrointestinal problems.

Improved quality of life: Ferric Maltol has been found to improve the quality of life in patients with IBD who suffer from iron deficiency anemia, which can cause fatigue, weakness, and other symptoms.

Easy administration: An oral medication and can be administered by patients themselves, making it more convenient than intravenous iron therapy.

Versatility: can be used in various forms, including tablets, capsules, and oral solutions, making it a versatile medication.

Safety: generally safe and well-tolerated, with few reported adverse effects.

Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults

Objective: To review the pharmacology, efficacy, and safety of ferric maltol (FM), an oral iron formulation, for iron deficiency anemia (IDA). Data sources: A MEDLINE/PubMed and EMBASE (January 1, 1985, to June 19, 2020) literature search was performed using the...

Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension

Rationale & objective: Iron-deficiency anemia is common in patients with chronic kidney disease (CKD) not requiring kidney replacement therapy (KRT). We evaluated effects of oral iron replacement therapy with ferric maltol in these patients. Study design: Phase 3, double-blind, randomized,...